Healthcare Reimbursement Coverage Expanded for the LAP-BAND System.

Business Editors

SANTA BARBARA, Calif.--(BUSINESS WIRE)--April 15, 2003

Inamed Corporation (Nasdaq:IMDC), a global healthcare company, announced today that Humana, Inc., one of the nation's largest publicly traded health benefits companies, has expanded its coverage guidelines to include the LAP-BAND(R) System as a covered benefit for the treatment of morbid obesity.

Headquartered in Louisville, Kentucky, Humana, Inc. has approximately 6.6 million medical members, located primarily in 18 states and Puerto Rico. Humana offers coordinated health insurance coverage and related services to employer groups and government-sponsored plans. Because coverage varies among plans, individual members should check their specific policy to determine eligibility for the LAP-BAND System.

"I applaud the vision of Humana to include the LAP-BAND System as a covered benefit to treat their eligible patients who are morbidly obese. The LAP-BAND System, with its proven track record of safely reducing excess weight, will now be available to even more people struggling with this significant healthcare problem," said Nick Teti, Chairman, President and Chief Executive Officer of Inamed.

Inamed reported that at the end of 2002, reimbursement coverage for the LAP-BAND System had been established with healthcare insurers having a total of 22 million medical members in the United States. By helping patients achieve significant and sustained weight loss, the LAP-BAND System has been shown to significantly reduce the risk of co-morbidities associated with obesity such as diabetes, cardiovascular disease and hypertension, and may lower overall healthcare costs.

About the LAP-BAND System

The LAP-BAND System is the only FDA-approved adjustable and reversible device for obesity surgery that does not require cutting or stapling of the stomach, or gastrointestinal re-routing to bypass normal digestion. Patient benefits include lower mortality, reduced surgical trauma, complications, pain and scarring as well as shorter hospitalization and recovery time as compared to alternative obesity surgeries such as gastric bypass or vertical banded gastroplasty.

The LAP-BAND System was approved by the U.S. Food & Drug Administration in 2001 and has been used in Europe since 1993. Since its international clinical introduction in 1993, more than 100,000 LAP-BAND System procedures have been performed around the world. It is indicated for use in severely obese patients with a BMI over 40 and for patients with a BMI over 35 with a significant co-morbidity who have been unsuccessful in maintaining weight loss with other medical therapy. BMI (Body Mass Index) is a measure of body fat based on height and weight that applies to both adult men and women.

About Inamed Corporation

Inamed (Nasdaq:IMDC) is a global healthcare company with over 25 years of experience developing, manufacturing, and marketing innovative, high-quality, science-based products. Current products include breast implants for aesthetic augmentation and for reconstructive surgery; a range of dermal products to treat facial wrinkles; and minimally invasive devices for obesity intervention, including the LAP-BAND System for morbid obesity. The Company's website is www.inamed.com.

Forward-Looking Statements

This press release contains, in addition to historical information, forward-looking statements. Such statements are based on management's current estimates and expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Inamed is providing this information as of April 15, 2003 and expressly disclaims any duty to update information contained in this press release.

This press release contains forward-looking statements, including, without limitation, express and implied statements regarding Inamed's anticipated sales and product development. These forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied here. Readers are referred to the documents filed by Inamed Corporation with the Securities and Exchange Commission, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements, including but not limited to: exposure to product liability and intellectual property claims; exposure to liabilities that may not be adequately covered by insurance or for which there is no insurance; potential negative publicity concerning product safety; potential fluctuations in quarterly and annual results; the effect of changing accounting and public reporting rules and regulations; volatility of Inamed's stock price; changes in the economy and consumer spending; competition from existing and/or new products; failure or delay of clinical trials; uncertainty in receiving timely regulatory approval or market acceptance for new products; dependence on a single supplier for each of Inamed's silicone raw materials and bovine and human collagen-based products; failure to protect Inamed's intellectual property; adverse changes in the regulatory or legislative environment (both in the U.S. and internationally) affecting our business; and failure of our collaborative partners to perform. The information contained in this press release is a statement of Inamed's present intention, belief or expectation and is based upon, among other things, the existing regulatory environment, industry conditions, market conditions and prices, the economy in general and Inamed's assumptions. Inamed may change its intention, belief or expectation, at any time and without notice, based upon any changes in such factors, in Inamed's assumptions or otherwise. Inamed undertakes no obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

By including any information in this press release, Inamed does not necessarily acknowledge that disclosure of such information is required by applicable law or that the information is material.